Carthew P, Martin E A, White I N, De Matteis F, Edwards R E, Dorman B M, Heydon R T, Smith L L
MRC Toxicology Unit, Hodgkin Building, University of Leicester, United Kingdom.
Cancer Res. 1995 Feb 1;55(3):544-7.
Tamoxifen administered in the diet (420 ppm) to Wistar rats (TOX:P) for only 3 months caused cumulative hepatic DNA damage as assessed by 32P-postlabeling, consistent with the proposal that tamoxifen is a genotoxic carcinogen in this species. Promotion of tumor development with phenobarbital after discontinuation of dietary tamoxifen resulted in the formation of liver carcinomas after 9 months. At 12 and 20 months in this study, the majority of these rats had liver carcinomas. Rats treated with tamoxifen for 3 months but not promoted with phenobarbital also developed liver tumors over a longer period of time. These tumors were predominantly adenomas, with one carcinoma, and occurred at a lower incidence than the tumors produced by promotion with phenobarbital. Rats treated with phenobarbital alone did not develop tumors after 20 months. Tamoxifen-induced DNA adducts were relatively persistent, with only a 38% decrease 3 months after tamoxifen treatment had been discontinued. This demonstrates that, in a susceptible species (the rat), tamoxifen can cause initiation of liver cancer after only 3 months exposure. It is proposed that the persistence of such DNA adducts may account for the ability of phenobarbital to promote a high incidence of liver carcinoma, even after discontinuation of tamoxifen treatment. These data are relevant to the concern for women given prophylactic tamoxifen for long periods in that even if there is a relatively small amount of cumulative tamoxifen-induced liver DNA damage, liver tumors could be promoted by other agents, even after the cessation of tamoxifen treatment.
在饮食中给Wistar大鼠(TOX:P)投喂420 ppm的他莫昔芬仅3个月,通过32P后标记法评估发现可导致肝脏DNA累积损伤,这与他莫昔芬在该物种中是一种基因毒性致癌物的观点一致。在停止饮食投喂他莫昔芬后,用苯巴比妥促进肿瘤发展,9个月后导致肝癌形成。在本研究的12个月和20个月时,这些大鼠中的大多数患有肝癌。用他莫昔芬治疗3个月但未用苯巴比妥促进的大鼠在更长时间内也发生了肝脏肿瘤。这些肿瘤主要是腺瘤,有一例是癌,其发生率低于用苯巴比妥促进产生的肿瘤。单独用苯巴比妥治疗的大鼠在20个月后未发生肿瘤。他莫昔芬诱导的DNA加合物相对持久,在停止他莫昔芬治疗3个月后仅减少38%。这表明,在一个易感物种(大鼠)中,他莫昔芬仅暴露3个月就可导致肝癌起始。有人提出,这种DNA加合物的持久性可能解释了即使在停止他莫昔芬治疗后,苯巴比妥仍能促进肝癌高发的能力。这些数据与长期接受预防性他莫昔芬治疗的女性的担忧相关,因为即使他莫昔芬诱导的肝脏DNA累积损伤量相对较小,在停止他莫昔芬治疗后,其他因素仍可能促进肝脏肿瘤的发生。